MetaCap

Arvinas (ARVN) vs Indaptus Therapeutics (INDP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Indaptus Therapeutics (INDP) has outperformed Arvinas (ARVN) over the past year, gaining 52.4% versus a loss of 43.9%. Over five years, ARVN leads with a -91.8% price change compared with -98.3% for INDP. Indaptus Therapeutics is the larger company by market cap ($433.2 million vs $423.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARVN-43.92%INDP+52.43%
+167%+54%-60%
Nov 21, 20251 yearNov 20, 2026
ARVN-92.22%INDP-98.22%
+14%-45%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARVN versus INDP key metrics
MetricARVNINDP
Share price$6.46$2.82
Market cap$423.03M$433.16M
1-day change-4.15%-9.90%
YTD return-45.53%-3.09%
1-year return-43.92%+52.43%
5-year return-91.75%-98.26%
EPS (TTM)$-0.08$-3.16
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$262.60M—
Revenue growth (YoY)-0.30%—
Net income (latest FY)$-80.80M$-20.85M
Operating margin-45.13%—
Net margin-30.77%—
52-week high$14.51$5.96
52-week low$6.33$0.92
Distance from 52-week high-55.48%-52.68%
Analyst consensusbuy—
Avg. price target upside+116.72%—
Average volume848.52K712.87K
Shares outstanding65.49M153.60M
Employees2465
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • INDP has outperformed ARVN by 96.4 percentage points over the past year.

About Arvinas

ARVN stock →

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.

Health Care · Biotechnology: Pharmaceutical Preparations · 246 employees

About Indaptus Therapeutics

INDP stock →

Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

ARVN vs INDP FAQ

Which is bigger, Arvinas or Indaptus Therapeutics?

Indaptus Therapeutics (INDP) is larger, with a market capitalization of $433.16M compared with $423.03M for Arvinas (ARVN).

Which stock has performed better over the past year, ARVN or INDP?

INDP returned +52.43% over the past 12 months, compared with -43.92% for ARVN (price return, excluding dividends). Past performance does not predict future results.

Are Arvinas and Indaptus Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons